Dear All, We are swimming in Broad Agency Announcements aka BAAs! As a refresher, I recently shared a BAA from the CDC and one from BARDA — now we have another one from NIAID! There’s a strong biodefense angle here with lots of scope. Key details of each opportunity are as follows and I highly recommend you check
Dear All, Building on the success of the 21st Century Cures Act passed in 2016 and springboarding from a concept paper published in Science, U.S. Reps. Diana DeGette, D-Colorado, and Fred Upton, R-Michigan, have today introduced the 21st Century Cures Act v2.0! Here are the links you need: Discussion draft of the Cures 2.0 bill Cures 2.0
Dear All (wonkish alert, but the details are fascinating … and with thanks to Kevin Outterson for co-authoring!), Two related items of note for today. First, the PASTEUR Act was introduced today (press release from Rep. Doyle; press release from Rep. Ferguson) into the US House of Representatives by the bipartisan team of U.S. Representatives
Dear All, First up for today, WHO’s GLASS (Global Antimicrobial Resistance and Use Surveillance System) have released an update to their ongoing work that provides global data through 2020. Here the links you need: The GLASS dashboard The GLASS report An insightful LinkedIn post on the way(s) that the data can now be used: you
Dear All, Continuing on the theme of helping countries develop their own national action plans, WHO released the “WHO implementation handbook for national action plans on antimicrobial resistance: guidance for the human health sector“. The handbook has some great infographics like the one below and will shortly be translated into French, Spanish, and Russian. There
Dear All, The US Office of the Assistant Secretary for Preparedness & Response (ASPR) is looking for comments on the 2023-2026 National Health Security Strategy (NHSS). They would like input from stakeholders in public health, healthcare, emergency management, national security, non-governmental organizations, academia, and private industry. Their specific questions to consider are: What are the most critical national health
Dear All, Four big reports have recently been released and are very much worth reviewing. First, the Global AMR R&D Hub and the WHO AMR Team have written a report entitled “Incentivising the development of new antibacterial treatments“. This report is a response to a 2021 request by the G7 Finance Ministers for a report on
Dear All, Excitingly, NIAID has released a new BAA (Broad Agency Announcement) entitled “Diagnostics Pre-Clinical Services Program.” Similar to the prior BAA for support of biopharmaceutical product development, this new BAA for diagnostic devices seeks a group who can manage a “multiple award Indefinite Delivery/Indefinite Quantity (IDIQ) type contract” (read that slowly!) and through it offer a comprehensive
Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the Boston Consulting Group and Wellcome Trust have examined at length the questions of (i) how the #FireExtinguishersOfMedicine are made and (ii) how they can be made with the least impact
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), We’ve written before about the UK’s “Netflix” pilot antibiotic Pull incentive in which England leads the way on showing how it plans to provide its fair share of a global antibacterial Pull incentive (for background on Pull incentives, see this superb 5-minute video explainer). In
